AUTHORS
Mary Lynn Savoie, MD, FRCPC, Bingshu Chen2, Karen-Sue Carlson, PhD, MD3, Ioannis Mantzaris, MD, MS4, Heather Male, MD5, Manuel Ricardo Espinoza-Gutarra, MD6, Olatoyosi Odenike Jr, MD7, Gail McDonald8, Lois Shepherd9, Richard Stone, MD10, Selina Luger, MD, FRCPC11, Harry Erba, MD, PhD12, Mark R. Litzow, MD13, Richard F. Little, MD14, Ehab Atallah, MD15, Megan Othus, PhD16, Sarit E. Assouline, MDCM, MSc, FRCPC17
AFFILIATIONS
1 University of Calgary, Calgary, Canada
2 Canadian Clinical Trials Group, Kingston, Canada
3 Medical College of Wisconsin, Milwaukee, United States
4 Montefiore Einstein Comprehensive Cancer Center, New York, United States
5 University of Kansas Medial Center, Kansas, United States
6 O'Neal Comprehensive Cancer Center at UAB, Birginham, United States
7 University of Chicago, Chicago, United States
8 Canadian Clinical Trials Group, Kingston, Canada
9 Canadian Clinical Trials Group, Kingston, Canada
10 Dana Farber Cancer Institute, Boston, United States
11 Hospital of the University of Pennsylvania, Pennsylvania, United States
12 University of Alabama at Birmingham, Durham, United States
13 Mayo Clinic, Rochester, United States
14 National Cancer Institute, Washington, United States
15 Medical College of Wisconsin, Milwaukee, United States
16 Fred Hutchinson Cancer Centre, Seattle, United States
17 McGill University, Montreal, Canada
ABSTRACT
Background and Significance:
Younger adults with intermediate-risk AML continue to experience substantial relapse risk despite intensive chemotherapy. Outcomes in this group are heterogeneous, and current standard treatment does not cure many patients. Venetoclax combinations have shown encouraging activity in early studies, raising the possibility of improving remission durability and survival compared with standard chemotherapy alone. However, these newer approaches have not yet been definitively shown to be superior to current standard therapy in this patient population. MM1YA-CTG01 (AL.6) evaluates
whether adding venetoclax to induction chemotherapy or treating with venetoclax and azacitidine improves remission and minimal residual disease (MRD) rate compared with standard therapy in a randomized setting.
Study Design and Methods:
myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a National Cancer Institute–led precision medicine platform trial that uses rapid genomic profiling to match patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to biomarker-driven treatment substudies. Subjects are enrolled onto the myeloMATCH Master Screening and Reassessment Protocol (NCT05564390) and are then assigned to MM1YA-CTG01 (AL.6) (NCT05554393) based on the presence of intermediate risk disease (ELN 2017).
MM1YA-CTG01 (AL.6) is a randomized, phase 2 trial enrolling adult patients aged 18 to 59 with AML (blasts >20%), with adequate organ function. Patients with high risk, core binding factor (CBF), NPM1 mutated, or FLT3-ITD AML are excluded. Patients are randomized 1:1:1 to 7+3 (daunorubucin 60 mg/m2/d days 1, 2, 3 and cytarabine 100 mg/m2/day days 1 to 7), venetoclax (400 mg days 1 to 28, with a ramp-up) and azacitidine (75 mg/m2/d days 1 –7; or 1-5, 8-9), or 7+3+venetoclax (venetoclax days 1- 11, with a ramp-up). The primary endpoint is MRD negative complete remission (CR) by flow cytometry, after induction chemotherapy or two cycles of venetoclax and azacitidine. Secondary endpoints include the assessment of treatment-related toxicities, remission rates (CR/CRi), event free, relapse free and overall survival, and correlations between clinical outcomes and genomic characteristics to inform precision treatment strategies. Exploratory analyses will evaluate molecular subgroups and treatment trajectories to generate hypotheses for future studies. For the comparison of each experimental arm with the control arm with one-sided significant level alpha = 0.10, to have an 80% power to detect a difference of 20% in MRD negative CR (74% versus 54%), 51 patients per arm will be enrolled, for a total of 153 patients.
MM1YA-CTG01 (AL.6) is a multisite, pan-NCTN study activated on July 18th, 2024, and is anticipated to enroll subjects through December 2027. To date, 35 patients have been enrolled; 27 have completed treatment. Median age is 52, 17 (50%) are male, 26 (70%) white, 19 (56%) ECOG PS 0, 13 patients with ECOG PS 1, and 2 with ECOG PS 2. The study is currently enrolling in the United States and Canada.
DISCLOSURES
Mary Lynn Savoie, MD, FRCPC: Johnson & Johnson - Honoraria; Merck - Honoraria; Jazz - Honoraria; Abbvie - Honoraria; Astellas - Honoraria; Amgen - Honoraria; Servier - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Novartis - Honoraria